VANCOUVER, British Columbia, April 30, 2019 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V: ENW | FSE:E4U) (“EnWave”, or the "Company") announced today that it has signed a Purchase Requisition (the "Agreement") with the United States Army Combat Capabilities Development Command Soldier Center to supply a second Radiant Energy Vacuum (“REV™”) machine to help further the development efforts focused on improving the quality of Close Combat Assault Rations and their subsequent deployment.
After a successful presentation at the Pentagon in May 2018 and confirmed internal demand for REV™ dried rations, the CCDC Soldier Center purchased their first REV™ machine and fast tracked the research and development necessary for implementation with close combat warfighters. Since that time, the CCDC Soldier Center has made significant product development progress in several areas and has also begun collaborating with the U.S. Army’s approved supplier network.
EnWave and the CCDC Soldier Center will continue to collaborate with potential vendors to manufacture and supply REV™-dried, nutrient rich field rations for the United States Army. Any interested parties are encouraged to contact EnWave Corporation at info@enwave.net.
About the U.S Army Combat Capabilities Development Command Soldier Center (CCDC-SC)
Formerly known as the U.S. Army Natick Soldier Research, Development and Engineering Center (NSRDEC), the U.S Army Combat Capabilities Development Command Soldier Center optimizes and modernizes individual Soldier and squad performance, and increases combat readiness and lethality to ensure dominance in multi-domain operations. CCDC Soldier Center uses science and engineering expertise, in collaboration with our DoD, industry and academia partners in the innovation ecosystem, to advance Soldier/squad performance optimization, readiness, lethality, and synthetic training environments. The CCDC Soldier Center’s research and development focus is concentrated on six core domains, each of which provide exactly what the Soldier needs given the unique combat environment in which they serve. These include: Basic & Early Applied Research; Clothing & Protective Equipment; Airdrop/Aerial Delivery; DoD Combat Feeding; Expeditionary Maneuver Support; Soldier/Small Combat Unit Technology Maturation & Demonstration; Human Systems Integration Sciences; and DoD Combat Feeding. These Soldier Center ensures our Soldiers are optimized, protected, and lethal.
About EnWave
EnWave Corporation, a Vancouver-based advanced technology company, has developed Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products.
REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with industry leaders in multiple verticals for the use of REV™ technology. The company has signed over twenty royalty-bearing licenses to date, opening up nine distinct market sectors for commercialization of new and innovative products. In addition to these licenses, EnWave has formed a Limited Liability Corporation, NutraDried Food Company, LLC, to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese® brand.
EnWave has introduced REV™ as the new dehydration standard in the food and biological material sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms:
- nutraREV® which is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour;
- powderREV® which is used for the bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes below the freezing point, and
- quantaREV® which is used for continuous, high-volume low-temperature drying.
An additional platform, freezeREV®, is being developed as a new method to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.
EnWave Corporation
Mr. Brent Charleton, CFA
President & CEO
For further information:
Brent Charleton, CFA , President & CEO at +1 (778) 378-9616
E-mail: bcharleton@enwave.net
John P.A. Budreski, Executive Chairman at +1 (416) 930-0914
E-mail: jbudreski@enwave.net
Deborah Honig, Corporate Development, Adelaide Capital Markets at + 1 (647) 203-8793
E-mail: dhonig@enwave.net
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.